Postinfusion variables in patients by occurrence of PSN
| Variable . | No PSN (n = 122) . | PSN (n = 22) . | Overall (N = 144) . | P value . |
|---|---|---|---|---|
| pRBC transfusions required | <.01 | |||
| No | 86 (97.7%) | 2 (2.3%) | 88 (61.1%) | |
| Yes | 33 (63.5%) | 19 (36.5%) | 52 (36.1%) | |
| Missing | 3 (75%) | 1 (25%) | 4 (2.8%) | |
| Platelet transfusions required | <.01 | |||
| No | 96 (99%) | 1 (1%) | 97 (67.4%) | |
| Yes | 24 (53.3%) | 21 (46.7%) | 45 (31.3%) | |
| Missing | 2 (100%) | 0 (0%) | 2 (1.4%) | |
| Coagulopathy | <.01 | |||
| No | 105 (89.7%) | 12 (10.3%) | 117 (81.3%) | |
| Yes | 11 (55%) | 9 (45%) | 20 (13.9%) | |
| Missing | 6 (85.7%) | 1 (14.3%) | 7 (4.9%) | |
| CRS | .02 | |||
| No | 54 (93.1%) | 4 (6.9%) | 58 (40.3%) | |
| Yes | 68 (80%) | 17 (20%) | 85 (59%) | |
| Missing | 0 (0%) | 1 (100%) | 1 (0.7%) | |
| ASTCT CRS | <.01 | |||
| 0 | 51 (92.7%) | 4 (7.3%) | 55 (38.2%) | |
| 1 | 34 (94.4%) | 2 (5.6%) | 36 (25%) | |
| 2 | 20 (83.3%) | 4 (16.7%) | 24 (16.7%) | |
| 3 | 12 (75%) | 4 (25%) | 16 (11.1%) | |
| 4 | 4 (33.3%) | 8 (66.7%) | 12 (8.3%) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| Severe CRS∗ | <.01 | |||
| No | 105 (91.3%) | 10 (8.7%) | 115 (79.9%) | |
| Yes | 16 (57.1%) | 12 (42.9%) | 28 (19.4%) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| ICANS | .02 | |||
| No | 100 (88.5%) | 13 (11.5%) | 113 (78.5%) | |
| Yes | 21 (70.0%) | 9 (30.0%) | 30 (20.8%) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| Max grade of ICANS | .07 | |||
| 0 | 100 (88.5%) | 13 (11.5%) | 113 (78.5%) | |
| 1 | 12 (80%) | 3 (20%) | 15 (10.4%) | |
| 2 | 4 (80%) | 1 (20%) | 5 (3.5%) | |
| 3 | 3 (42.9%) | 4 (57.1%) | 7 (4.9%) | |
| 4 | 2 (66.7%) | 1 (33.3%) | 3 (2.1%) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| CRS with HLH-like toxicities | <.01 | |||
| No | 117 (90.7%) | 12 (9.3%) | 129 (89.6%) | |
| Yes | 5 (33.3%) | 10 (66.7%) | 15 (10.4%) | |
| Intensive care required (days) | <.01 | |||
| Median (IQR) | 0 (0-0) | 6 (0-10.5) | 0 (0-2) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| Peak ferritin (ng/mL) | <.01 | |||
| Median (IQR) | 1580 (637-3520) | 40 000 (11 800-157 000) | 2300 (900-9050) | |
| Missing | 17 (85%) | 3 (15%) | 20 (13.9%) | |
| Peak CRP (mg/dL) | <.01 | |||
| Median (IQR) | 2.35 (0.8-10) | 15.6 (7.63-32) | 3.27 (0.900-11.6) | |
| Missing | 20 (76.9%) | 6 (23.1%) | 26 (18.1%) | |
| No. of doses of tocilizumab | <.01 | |||
| Median (IQR) | 0 (0-0) | 1 (0-2) | 0 (0-0) | |
| Missing | 7 (87.5%) | 1 (12.5%) | 8 (5.6%) | |
| No. of days of steroid | .16 | |||
| Median (IQR) | 0 (0-0) | 0.50 (0-4.25) | 0 (0-0) | |
| Missing | 10 (83.3%) | 2 (16.7%) | 12 (8.3%) | |
| Infection within 30 days after CAR-Ts | .03 | |||
| No | 107 (87.7%) | 15 (12.3%) | 122 (84.7%) | |
| Yes | 15 (68.2%) | 7 (31.8%) | 22 (15.3%) | |
| Time from CAR-Ts to earliest infection (days)† | ‡ | |||
| Median (IQR) | 87 (10-211) | 17.5 (6.25-47.5) | 50 (10-192) | |
| Missing | 0 (0%) | 1 (100%) | 1 (1.9%) |
| Variable . | No PSN (n = 122) . | PSN (n = 22) . | Overall (N = 144) . | P value . |
|---|---|---|---|---|
| pRBC transfusions required | <.01 | |||
| No | 86 (97.7%) | 2 (2.3%) | 88 (61.1%) | |
| Yes | 33 (63.5%) | 19 (36.5%) | 52 (36.1%) | |
| Missing | 3 (75%) | 1 (25%) | 4 (2.8%) | |
| Platelet transfusions required | <.01 | |||
| No | 96 (99%) | 1 (1%) | 97 (67.4%) | |
| Yes | 24 (53.3%) | 21 (46.7%) | 45 (31.3%) | |
| Missing | 2 (100%) | 0 (0%) | 2 (1.4%) | |
| Coagulopathy | <.01 | |||
| No | 105 (89.7%) | 12 (10.3%) | 117 (81.3%) | |
| Yes | 11 (55%) | 9 (45%) | 20 (13.9%) | |
| Missing | 6 (85.7%) | 1 (14.3%) | 7 (4.9%) | |
| CRS | .02 | |||
| No | 54 (93.1%) | 4 (6.9%) | 58 (40.3%) | |
| Yes | 68 (80%) | 17 (20%) | 85 (59%) | |
| Missing | 0 (0%) | 1 (100%) | 1 (0.7%) | |
| ASTCT CRS | <.01 | |||
| 0 | 51 (92.7%) | 4 (7.3%) | 55 (38.2%) | |
| 1 | 34 (94.4%) | 2 (5.6%) | 36 (25%) | |
| 2 | 20 (83.3%) | 4 (16.7%) | 24 (16.7%) | |
| 3 | 12 (75%) | 4 (25%) | 16 (11.1%) | |
| 4 | 4 (33.3%) | 8 (66.7%) | 12 (8.3%) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| Severe CRS∗ | <.01 | |||
| No | 105 (91.3%) | 10 (8.7%) | 115 (79.9%) | |
| Yes | 16 (57.1%) | 12 (42.9%) | 28 (19.4%) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| ICANS | .02 | |||
| No | 100 (88.5%) | 13 (11.5%) | 113 (78.5%) | |
| Yes | 21 (70.0%) | 9 (30.0%) | 30 (20.8%) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| Max grade of ICANS | .07 | |||
| 0 | 100 (88.5%) | 13 (11.5%) | 113 (78.5%) | |
| 1 | 12 (80%) | 3 (20%) | 15 (10.4%) | |
| 2 | 4 (80%) | 1 (20%) | 5 (3.5%) | |
| 3 | 3 (42.9%) | 4 (57.1%) | 7 (4.9%) | |
| 4 | 2 (66.7%) | 1 (33.3%) | 3 (2.1%) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| CRS with HLH-like toxicities | <.01 | |||
| No | 117 (90.7%) | 12 (9.3%) | 129 (89.6%) | |
| Yes | 5 (33.3%) | 10 (66.7%) | 15 (10.4%) | |
| Intensive care required (days) | <.01 | |||
| Median (IQR) | 0 (0-0) | 6 (0-10.5) | 0 (0-2) | |
| Missing | 1 (100%) | 0 (0%) | 1 (0.7%) | |
| Peak ferritin (ng/mL) | <.01 | |||
| Median (IQR) | 1580 (637-3520) | 40 000 (11 800-157 000) | 2300 (900-9050) | |
| Missing | 17 (85%) | 3 (15%) | 20 (13.9%) | |
| Peak CRP (mg/dL) | <.01 | |||
| Median (IQR) | 2.35 (0.8-10) | 15.6 (7.63-32) | 3.27 (0.900-11.6) | |
| Missing | 20 (76.9%) | 6 (23.1%) | 26 (18.1%) | |
| No. of doses of tocilizumab | <.01 | |||
| Median (IQR) | 0 (0-0) | 1 (0-2) | 0 (0-0) | |
| Missing | 7 (87.5%) | 1 (12.5%) | 8 (5.6%) | |
| No. of days of steroid | .16 | |||
| Median (IQR) | 0 (0-0) | 0.50 (0-4.25) | 0 (0-0) | |
| Missing | 10 (83.3%) | 2 (16.7%) | 12 (8.3%) | |
| Infection within 30 days after CAR-Ts | .03 | |||
| No | 107 (87.7%) | 15 (12.3%) | 122 (84.7%) | |
| Yes | 15 (68.2%) | 7 (31.8%) | 22 (15.3%) | |
| Time from CAR-Ts to earliest infection (days)† | ‡ | |||
| Median (IQR) | 87 (10-211) | 17.5 (6.25-47.5) | 50 (10-192) | |
| Missing | 0 (0%) | 1 (100%) | 1 (1.9%) |